A Study to Assess the Systemic Pharmacokinetics, Metabolism and Excretion Routes of YM178 in Man, After Administration of Radio-labeled YM178
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The study aims to assess the routes and the extent of metabolism and excretion of YM178 after a single dose of 14C-radiolabeled YM178 administered as a drinking solution in healthy male volunteers.
| Condition | Intervention | Phase |
|---|---|---|
|
Metabolic Processes |
Drug: 14C-labeled YM178 |
Phase 1 |
| Study Type: | Interventional |
| Study Design: | Endpoint Classification: Pharmacokinetics Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Basic Science |
| Official Title: | An Open-label Study to Evaluate the Pharmacokinetics of YM178 After Single Oral Administration of 14C-labeled YM178 in Healthy Male Volunteers |
- The assessment of pharmacokinetic profile of radioactivity after single-dose administration of 14C-YM178, measured by whole blood and plasma concentration [ Time Frame: Baseline to Day 5 (optional (Day 6-8) [maximum of 19 assessments] ] [ Designated as safety issue: No ]Cmax, tmax, AUC0-last, AUC0-inf, t1/2 and the blood-to-plasma ratio (Ratio Cb/p)
- The excretion rate and cumulative excretion of radioactivity in urine, feces and expired air after single-dose administration of 14C-YM178 [ Time Frame: Baseline to Day 5 (optional (Day 6-8) [maximum of 10 assessments] ] [ Designated as safety issue: No ]
- The assessment of pharmacokinetic profile of parent YM178 after single-dose administration of 14C-YM178, measured plasma and urine concentration [ Time Frame: Baseline to Day 5 (optional (Day 6-8) [maximum of 19 assessments] ] [ Designated as safety issue: No ]plasma (Cmax, tmax, AUC0-last, AUC0-inf, t1/2 and Vz/F), urine (Ae0-24, Ae0-last, CLR and % dose excreted)
- Safety assessed through Adverse Events, vital signs, laboratory analyses and ECG (electrocardiogram) [ Time Frame: Through to Day 19 ] [ Designated as safety issue: Yes ]
| Enrollment: | 4 |
| Study Start Date: | January 2003 |
| Study Completion Date: | February 2003 |
| Primary Completion Date: | February 2003 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: 14C-labeled YM178
Single oral administration of 14C-labeled YM178
|
Drug: 14C-labeled YM178
oral solution (1.85 MBq)
Other Names:
|
Detailed Description:
Four subjects are studied in one group. Each subject stays in the clinic for 6 days, and receives a single oral dose of 14C-labeled YM178. Blood, plasma, urine, feces and expired air are collected for 96h after dosing.
If 14C-radioactivity quick counts show that radioactivity in urine or feces is above acceptable limits (ie. > 50 dpm/ml in urine; >75 dpm in 400 mg feces) on day 5, subjects are requested to stay in the clinic until the levels decrease. If, after 3 days, radioactivity is still > 50 dpm/ml in urine and/or >75 dpm in 400 mg feces, urine and/or feces is collected at home, until the amount of radioactivity decreases.
Eligibility| Ages Eligible for Study: | 18 Years to 55 Years |
| Genders Eligible for Study: | Male |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Body weight between 60 and 100 kg, and BMI ≤30 kg/m2
Exclusion Criteria:
- Known or suspected hypersensitivity to β-adrenergic receptor agonists or constituents of the formulations used
- Any clinically significant history of asthma, eczema, any other allergic condition or previous severe hypersensitivity to any drug
- Any clinically significant history of upper gastrointestinal symptoms (such as nausea, vomiting, abdominal discomfort or upset, or heartburn) in the 4 weeks prior to admission to the Research Unit
- Any clinically significant history of any other disease or disorder - gastrointestinal, cardiovascular, respiratory, renal, hepatic, neurological, dermatological, psychiatric or metabolic
- Abnormal pulse rate measurement (<40 or >90 bpm) taken by manual counting at the pre-study visit after subject has been resting in supine position for 5 min
Abnormal blood pressure measurements taken at the pre-study visit after subject has been resting in supine position for 5 min as follows:
- Systolic blood pressure <95 or >160 mmHg;
- Diastolic blood pressure <40 or >95 mmHg.
- Positive orthostatic test at screening i.e. any symptoms of dizziness, light-headedness etc. and/or a fall of ≥ 20 mmHg in systolic blood pressure after 2 min standing (preceded by 5 min. supine rest) and/or an increase in pulse rate of ≥ 20 bpm
- Regular use of any prescribed or OTC (over the counter) drugs except paracetamol up to 3 g/day, in the 4 weeks prior to admission to the Research Unit OR any use of such drugs in the 2 weeks prior to admission to the Research Unit
- History of drug abuse at any time, OR any use of drugs of abuse within 3 months prior to admission to the Research Unit
- History of smoking more than 10 cigarettes (or equivalent amount of tobacco) per day within 3 months prior to admission to the Research Unit
- History of drinking more than 21 units of alcohol per week (1 unit = 270 cc of beer or 40 cc of spirits or 1 glass of wine) within 3 months prior to admission to the Research Unit
- Donation of blood or blood products within 3 months prior to admission to the Research Unit
- Positive serology test for HBsAg, HAV IgM, anti-HCV or anti-HIV 1+2.
- Participation in any clinical study within 3 months, or participation in more than 3 clinical studies within 12 months, prior to the expected date of enrolment into the study
- Subjects having received YM178 previously
- Exposure to radiation for diagnostic reasons (except dental X-rays and plain X-rays of thorax and bony skeleton (excluding spinal column)), during work or during participation in a clinical trial in the previous year
Contacts and Locations
More Information
No publications provided
| Responsible Party: | Astellas Pharma Inc ( Astellas Pharma Europe BV ) |
| ClinicalTrials.gov Identifier: | NCT01651312 History of Changes |
| Other Study ID Numbers: | 178-CL-007 |
| Study First Received: | July 23, 2012 |
| Last Updated: | July 25, 2012 |
| Health Authority: | Netherlands: Medical Ethics Review Committee (METC) |
Keywords provided by Astellas Pharma Inc:
|
Radioactivity Excretion rate Human subjects Pharmacokinetics |
YM178 Radio-labeled Phase 1 |
ClinicalTrials.gov processed this record on May 23, 2013